Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control

References

• BasileJNChrysantSThe importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapyJ Hum Hypertens200620316917516397516
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• WeirMRCrikelairNLevyDRochaRKuturuVGlazerREvaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertensionJ Clin Hypertens (Greenwich)20079210311217268215
   PubMedGoogle Scholar
• WeirMRLevyDCrikelairNRochaRMengXGlazerRTime to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapyAm J Hypertens200720780781517586417
   PubMed Web of Science ®Google Scholar
• SteffenHMAmlodipine – a third generation dihydropyridine calcium antagonistJ Clin Basic Cardiol1999214552
   Google Scholar
• TylerHMAmlodipine: an effective once-daily antihypertensive agentJ Hum Hypertens19915Suppl 161661834848
   PubMedGoogle Scholar
• WagstaffAJValsartan/hydrochlorothiazide: a review of its use in the management of hypertensionDrugs200666141881190117040120
   PubMed Web of Science ®Google Scholar
• PoolJLGlazerRWeinbergerMAlvaradoRHuangJGraffAComparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adultsClin Ther2007291617317379047
   PubMed Web of Science ®Google Scholar
• PalatiniPMalaccoEDiSSTrough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipineEur J Clin Pharmacol2002571176577011868797
   PubMedGoogle Scholar
• WeirMRFerdinandKCFlackJMJamersonKADaleyWZelenkofskeSA noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensivesHypertension200546350851316116046
   PubMedGoogle Scholar
• RuilopeLMMalaccoEKhderYKandraABönnerGHeintzDEfficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST studyClin Ther200527557858715978306
   PubMed Web of Science ®Google Scholar
• RuilopeLMHeintzDBrandaoAA24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-studyBlood Press Monit2005102859115812256
   PubMedGoogle Scholar
• LacourcièreYWrightJTJrSamuelRZappeDPurkayasthaDBlackHREffects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE studyBlood Press Monit200914311212019384192
   PubMed Web of Science ®Google Scholar
• PerloffDGrimCFlackJHuman blood pressure determination by sphygmomanometryCirculation199388(5 Pt 1):246024708222141
   PubMed Web of Science ®Google Scholar
• NeutelJMThe use of combination drug therapy in the treatment of hypertensionProg Cardiovasc Nurs2002172818811986541
   PubMedGoogle Scholar
• NickenigGOstergrenJStruijker-BoudierHClinical evidence for the cardiovascular benefits of angiotensin receptor blockersJ Renin Angiotensin Aldosterone Syst20067Suppl 1S1S716969748
   PubMed Web of Science ®Google Scholar
• WeirMRProviding end-organ protection with renin-angiotensin system inhibition: the evidence so farJ Clin Hypertens (Greenwich)2006829910516470078
   PubMedGoogle Scholar
• National Institute for Health and Clinical ExcellenceHypertension Management of hypertension in adults in primary careNICE clinical guideline 34. 2006Available at: http://www.nice.org.uk/nicemedia/pdf/cg034niceguideline.pdf Accessed June 2008.
   Google Scholar
• BrownMJCruickshankJKDominiczakAFBetter blood pressure control: how to combine drugsJ Hum Hypertens2003172818612574784
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• SicaDACombination ACE inhibitor and angiotensin receptor blocker therapy – future considerationsJ Clin Hypertens (Greenwich)200791788617215664
   PubMedGoogle Scholar
• DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• PalatiniPMugelliniASpagnuoloVComparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study)Blood Press Monit200492919715096906
   PubMedGoogle Scholar
• MalaccoEVariNCapuanoVSpagnuoloVBorgninoCPalatiniPA randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst studyClin Ther200325112765278014693303
   PubMedGoogle Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFAssessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or bothClin Ther200426446047215189744
   PubMedGoogle Scholar
• OparilSYarowsSAPatelSFangHZhangJSatlinAEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trialLancet2007370958322122917658393
   PubMed Web of Science ®Google Scholar
• HermidaRCAyalaDEKhderYCalvoCAmbulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: A prospective, randomized, open-label, blinded end-point trialClin Ther200830110812018343247
   PubMedGoogle Scholar
• MaillardMPWürznerGNussbergerJCentenoCBurnierMBrunnerHRComparative angiotensin II receptor blockade in healthy volunteers: the importance of dosingClin Pharmacol Ther2002711687611823759
   PubMed Web of Science ®Google Scholar
• LatifFTandonSObelenieneRAngiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjectsJ Card Fail20017326526811561228
   PubMed Web of Science ®Google Scholar
• OsterlohIThe safety of amlodipineAm Heart J1989118(5 Pt 2): 111411192573265
   PubMed Web of Science ®Google Scholar
• ElliottWJWhat factors contribute to the inadequate control of elevated blood pressure?J Clin Hypertens (Greenwich)2008101 Suppl 1202618174780
   PubMed Web of Science ®Google Scholar